Pfizer and Moderna stocks tumble over anticipated low COVID-19 vaccination rate

  • 📰 dcexaminer
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 94%

Business News News

Business Business Latest News,Business Business Headlines

Pfizer, BioNTech, and Moderna stock prices fell precipitously on Monday as a result of anticipated low uptake rates for the updated COVID-19 vaccines.

Pfizer CFO David Denton said at a press conference on Monday that he anticipates 24% of the U.S. population, or 82 million people, will receive the updated COVID-19 vaccines that received approval from the Food and Drug Administration last week.As of May, only 17% of the nation had received the bivalent booster vaccination against COVID-19, according to data from the Centers for Disease Control and Prevention.

Pfizer and BioNTech announced on Tuesday of last week at a CDC advisory meeting that they would be charging approximately $120 for their mRNA COVID-19 vaccines, while Moderna would be charging closer to $130. The Biden administration announced in July that it would begin commercializing the COVID-19 preparedness strategy, only relying upon government-purchased vaccines for those without insurance or with insurance that would not cover the updated shot.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stocks making the biggest moves midday: Marathon Petroleum, Tesla, Moderna and moreThese are the stocks posting the largest moves in midday trading.
Source: CNBC - 🏆 12. / 72 Read more »